CONTACT:
Douglas M. Tucker, PhD, MBA
Neurognostics, Inc.
Phone: 414-727-7950 x 110
Fax: 414-727-7952
E-mail: dtucker@neurognostics.com
Website: www.neurognostics.com
Milwaukee, WI, October 24, 2005 – Neurognostics, Inc., a Wisconsin company specializing in functional Magnetic Resonance Imaging (fMRI) products and services, was honored with a Wisconsin Small Business Innovation Award for Outstanding Achievements.
The award was presented by Wisconsin Small Business Innovation Consortium (WiSBIC) during its 19th annual Awards Banquet. WiSBIC was created to help technology-based and other innovative small businesses in securing research and development funding, commercializing their products, and growing and expanding their business.
Cathy Elsinger, Ph.D., Neurognostics’ Director of Research and Clinical Operations, accepted the award on behalf of Neurognostics. “We are grateful to be presented this award,” said Dr. Elsinger. “It is nice to see that the state of Wisconsin recognizes the achievements of small businesses and supports them during the crucial early stages of their development.”
Last year Neurognostics received a Phase I Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) to begin the development and validation of fMRI-based biomarkers in Parkinson’s disease. The Company is currently preparing the Phase II submission based on the Phase I results, as well as exploring other SBIR opportunities.
Founded in 2003, Neurognostics develops clinical applications for fMRI. Neurognostics strives to standardize the way fMRI is performed in a clinical setting, whether it is used in preoperative neurosurgical procedures or to assess and manage patients with various neurological and neurodevelopmental disorders. fMRI is a powerful imaging technique that extends the capability of Magnetic Resonance (MR) imaging by providing information about the functioning of imaged tissue. The Company hopes that its applications will become the standard technique to assess and manage patients with CNS disorders.
